News & Updates

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.

Once-only screening with flexible sigmoidoscopy appears to provide prolonged protection against colorectal cancer (CRC), reducing both incidence and mortality rates for up to 2 decades, according to the updated results of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Treatment with dostarlimab combined with carboplatin‒paclitaxel significantly improves overall survival (OS) among patients with primary advanced or recurrent endometrial cancer (EC), with no new safety signals, results of the RUBY trial have shown.

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.